Dr. Mitri on Neratinib and Pertuzumab in HER2-Amplified Breast Cancer

Video

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the use of neratinib (Nerlynx) and pertuzumab (Perjeta) in patients with HER2-amplified breast cancer.

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the use of neratinib (Nerlynx) and pertuzumab (Perjeta) in patients with HER2-amplified breast cancer.

In light of a recent subgroup analysis, there is a lot of talk whether physicians should use pertuzumab for ER-negative, HER2-amplified breast cancer and neratinib for ER-positive, HER2-amplified breast cancer, says Mitri. At this point, the primary endpoint in both studies was positive. If physicians want to do subgroup analyses, it seems that most of the benefit of neratinib is in the ER-positive subgroup.

For pertuzumab, the benefit is similar in both, but more so in the ER-negative subgroup. At this point, Mitri says he is sticking to the primary endpoint of the study. If physicians think that someone deserves pertuzumab upfront, they should offer neratinib subsequently. However, if someone has really bad tolerance to one or the other, then physicians have to address that. Though the overall survival was the same in the APHINITY study of pertuzumab and the ExteNET study of neratinib, the ER-negative subgroup did not seem to benefit, says Mitri.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD